本文選題：卒中 + 機(jī)械取栓��； 參考：《中國腦血管病雜志》2017年04期

【摘要】：目的比較血管事件總體健康風(fēng)險(THRIVE),多中心卒中調(diào)查(MSS),休斯敦動脈內(nèi)治療(HIAT)及葡萄糖水平、種族、年齡、性別、收縮壓水平、卒中程度(GRASPS)評分4種風(fēng)險模型預(yù)測急性前循環(huán)缺血性卒中機(jī)械取栓后腦出血與不良結(jié)局的效能。方法前瞻性連續(xù)性納入2013年5月至2016年3月收住南京大學(xué)附屬金陵醫(yī)院和廈門大學(xué)附屬中山醫(yī)院神經(jīng)內(nèi)科發(fā)病6 h內(nèi)的急性前循環(huán)大血管閉塞并實(shí)施機(jī)械取栓的患者153例。采用Logistic回歸分析和受試者工作特征(ROC)曲線下面積(AUC)探討THRIVE、MSS、HIAT、GRASPS評分4種風(fēng)險模型預(yù)測急性前循環(huán)缺血性卒中機(jī)械取栓后,腦出血與不良結(jié)局[包括90 d全因死亡和90 d改良Rankin量表(mRS)評分≥3分]的效能。結(jié)果 MSS評分(AUC為0.639,95%CI:0.548~0.730,P=0.004)和GRASPS評分(AUC為0.616,95%CI:0.525~0.706,P=0.017)能夠預(yù)測腦出血事件,但預(yù)測準(zhǔn)確性較低;4種模型對機(jī)械取栓后90 d內(nèi)死亡均有預(yù)測價值,其中GRASPS評分(AUC為0.783,95%CI:0.706~0.860,P0.001)有中等預(yù)測準(zhǔn)確性,其余3種模型AUC0.7,預(yù)測準(zhǔn)確性低;4種模型均能對90d不良預(yù)后(90 dmRS≥3分)進(jìn)行預(yù)測,其中GRASPS評分及THRIVE評分AUC均0.7,GRASPS評分AUC最大(AUC為0.782,95%CI:0.708~0.855,P0.01),兩者有中度預(yù)測準(zhǔn)確性。結(jié)論 GRASPS評分對機(jī)械取栓后90 d內(nèi)全因死亡及不良預(yù)后均有較好的臨床預(yù)測價值,THRIVE評分對90 d不良預(yù)后有較好的臨床預(yù)測價值。4種模型對機(jī)械取栓后腦出血事件的預(yù)測價值仍有待驗(yàn)證。
[Abstract]:Objective to compare the overall health risk of vascular events (THRIVE), multiple center stroke survey (MSSU), intra-arterial therapy (HI) in Houston and glucose levels, race, age, sex, systolic blood pressure (SBP). Efficacy of four risk models for predicting cerebral hemorrhage and adverse outcome after mechanical thrombectomy in patients with acute anterior circulation ischemic stroke. Methods from May 2013 to March 2016, 153 patients with acute anterior circulation macrovascular occlusion and mechanical thrombectomy were enrolled in the neurology department of Jinling Hospital affiliated to Nanjing University and Zhongshan Hospital affiliated to Xiamen University from May 2013 to March 2016. Using the Logistic regression analysis and the area under the operating characteristic curve of subjects, four risk models of THRIVE and MSSHIATATGRASPS score were used to predict the risk of mechanical thrombus removal after acute anterior circulatory ischemic stroke. Efficacy of intracerebral hemorrhage and adverse outcome [including 90 days of all-cause death and 90 days of modified Rankin scale with mRSs 鈮，

本文編號：1811393